Title: PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE

Abstract: The application relates to solid pharmaceutical compositions suitable for oral administration comprising a water sensitive drug, preferably an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions.
The present invention relates to solid pharmaceutical compositions suitable for oral administration comprising a water sensitive drug, preferably an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions.

Pharmaceutical compositions for oral administration in a solid form are in general known as well as methods of producing the same. For example, a tablet form may be produced by dry compression, e.g. direct compression or roller compaction. However, there is a need for a water sensitive drug, preferably an indolylmaleimide derivative, containing solid pharmaceutical composition which is adapted for oral administration, preferably in the form of a tablet. Also, there is a need for said compositions having a high drug load, e.g. a drug load greater than 20%.

Accordingly, the present invention provides a solid pharmaceutical composition suitable for oral administration comprising a water sensitive drug, preferably an indolylmaleimide derivative, suitable to achieve high drug loads.

It has now surprisingly been found a solid pharmaceutical composition comprising a water sensitive drug, preferably an indolylmaleimide derivative, suitable for oral administration. The composition according to the present invention may, in addition, show a high level of uniformity in the distribution of the drug as well as high stability. The composition according to the present invention may be manufactured on high speed automated equipment, avoiding time-consuming encapsulation techniques.

By water sensitive drug is meant an active agent which is highly soluble in water and in ethanol with a high powder-liquid ratio, e.g. a ratio of 10mg/ml, and which may convert either to a free base hydrate, a solvate or an amorphous form in the presence of ethanol and/or water.

More particularly the present invention relates to a solid pharmaceutical composition suitable for oral administration containing an indolylmaleimide derivative of formula X.
wherein $R_x$ is an aromatic or heterocyclic residue, e.g. as defined below, and $R_{x1}$ is H or a substituent, e.g. as indicated below, the indolyl residue being optionally further substituted, e.g. by one or 2 substituents.

Representative indolylmaleimide derivatives are e.g. compounds of formula I

wherein

- $R_a$ is H; C$_1$-alkyl; or C$_1$-alkyl substituted by OH, NH$_2$, NHC$_1$-alkyl or N(di-C$_1$-alkyl)$_2$;
- $R_b$ is H; or C$_1$-alkyl;
- $R$ is a radical of formula (a), (b), (c), (d), (e) or (f)
wherein each of \( R_1, R_4, R_7, R_8, R_{11} \) and \( R_{14} \) is OH; SH; a heterocyclic residue; \( NR_{19}R_{17} \) wherein each of \( R_{18} \) and \( R_{17} \), independently, is H or \( C_1\text{-}C_4\text{alkyl} \) or \( R_{16} \) and \( R_{17} \) form together with the nitrogen atom to which they are bound a heterocyclic residue; or a radical of formula \( \alpha \):

\[
-X-R_c-Y
\]

wherein \( X \) is a direct bond, O, S or \( NR_{18} \) wherein \( R_{18} \) is H or \( C_1\text{-}C_4\text{alkyl} \), \( R_c \) is \( C_1\text{-}C_4\text{alkylene} \) or \( C_1\text{-}C_4\text{alkylene} \) wherein one \( CH_2 \) is replaced by \( CR_aR_y \) wherein one of \( R_a \) and \( R_y \) is \( H \) and the other is \( CH_3 \); each of \( R_a \) and \( R_y \) is \( CH_3 \) or \( R_x \) and \( R_y \) form together \( -CH_2-CH_2- \); and

\( Y \) is bound to the terminal carbon atom and is selected from OH, a heterocyclic residue and \( -NR_{19}R_{20} \) wherein each of \( R_{19} \) and \( R_{20} \) independently is H, \( C_3\text{-}C_6\text{cycloalkyl} \), \( C_3\text{-}C_6\text{cycloalkyl}-C_1\text{-}C_4\text{alkyl} \), \( C_1\text{-}C_4\text{alkyloxy} \) or \( C_1\text{-}C_4\text{alkylthio} \), \( NH(C_1\text{-}C_4\text{alkyl})_2 \) or \( CN \);

\( \) either \( E \) is \( -N= \) and \( G \) is \( -CH= \) or \( E \) is \( -CH= \) and \( G \) is \( -N= \); and

\( \) ring A is optionally substituted.

Any alkyl or alkyl moiety in e.g. alkoxy may be linear or branched. Halogen may be F, Cl, Br or I, preferably F or Cl. Any aryl may be phenyl or naphthyl, preferably phenyl.

By heterocyclic residue as \( R_1, R_4, R_7, R_8, R_{11}, R_{14} \) or \( Y \) or formed, respectively, by \( NR_{18}R_{17} \) or \( NR_{18}R_{20} \), it meant a three to eight, preferably five to eight, membered saturated, unsaturated or aromatic heterocyclic ring comprising 1 or 2 heteroatoms, preferably selected from N, O and S, and optionally substituted. Suitable examples include e.g. pyridyl, e.g. 3- or 4-pyridyl, piperidyl, e.g. piperidin-1-yl, 3- or 4-piperidyl, homopiperidyl, piperezinyl, homopiperazinyl, morpholin-4-yl, imidazolyl, imidazolidinyl, pyrrolyl or pyrrolidinyl, optionally substituted, e.g. mono- or polysubstituted. When the heterocyclic residue is substituted, this may be on one or more ring carbon atoms and/or on a ring nitrogen atom when present. Examples of a substituent on a ring carbon atom include e.g. \( C_1\text{-}C_4\text{alkyl} \) e.g. \( CH_3 \):

\[
\begin{array}{c}
\text{CH}_3 \\
\text{CH}_3
\end{array}
\]

\( C_3\text{-}C_6\text{cycloalkyl} \) e.g. cyclopropyl, optionally further substituted by \( C_1\text{-}C_4\text{alkyl} \);

\[
\begin{array}{c}
\text{CH}_3 \\
\text{CH}_3
\end{array}
\]

wherein \( p \) is 1, 2 or 3, preferably 1; \( CF_3 \); halogen; OH; NH_2; -CH_2-NH_2; -CH_2-OH; piperidin-1-yl; or pyrrolidinyl. Examples of a substituent on a ring nitrogen atom are e.g. \( C_1\text{-}C_4\text{alkyl} \); acyl, e.g.
R'\text{\_CO} wherein R'_x is H, C\text{\_alkyl} or phenyl optionally substituted by C\text{\_alkyl}, C\text{\_alkoxy} or amino, e.g formyl; C\text{\_cycloalkyl}; C\text{\_cycloalkyl-C\text{\_alkyl}}; phenyl; phenyl-C\text{\_alkyl} e.g. benzyl; a heterocyclic residue, e.g. as disclosed above, e.g. an aromatic heterocyclic residue comprising 1 or 2 nitrogen atoms; or a residue of formula $\beta$

\[ -R_{21} - Y' \quad (\beta) \]

wherein $R_{21}$ is C\text{\_alkylene} or C\text{\_alkylene} interrupted by O and $Y'$ is OH, NH$_2$, NH(C\text{\_alkyl}) or N(C\text{\_alkyl})$_2$.

C\text{\_alkylene} interrupted by O may be e.g. -CH$_2$-CH$_2$-O-CH$_2$-CH$_2$-.

When the substituent on a cyclic nitrogen is a heterocyclic residue, it may be a five or six membered saturated, unsaturated or aromatic heterocyclic ring comprising 1 or 2 heteroatoms, preferably selected from N, O and S. Examples include e.g. 3- or 4-pyridyl, piperidyl, e.g. piperordin-1-yl, 3- or 4-piperidyl, homopiperidyl, piperaziny1, homopiperaziny1, pyrimidiny1, morpholin-4-yl, imidazolyl, imidazolidiny1, pyrroly1 or pyrrolidiny1.

When $R_8$ is substituted C\text{\_alkyl}, the substituent is preferably on the terminal carbon atom.

When ring A is substituted, it may be mono- or polysubstituted, preferably monosubstituted, the substituent(s) being selected from the group consisting of e.g. halogen, OH, C\text{\_alkoxy}, e.g. OCH$_3$, C\text{\_alkyl}, e.g. CH$_3$, NO$_2$, CF$_3$, NH$_2$, NHCO-C\text{\_alkyl}, N(di-C\text{\_alkyl})$_2$ and CN. For example, ring A may be a residue of formula $A$

\[
\begin{aligned}
\text{R}_8 \\
\text{R}_9 \\
\end{aligned}
\]

wherein

$R_9$ is H; C\text{\_alkyl}; or halogen; and

$R_8$ is OH; NO$_2$; NH$_2$; NHCO-C\text{\_alkyl}; or N(di-C\text{\_alkyl})$_2$.

Preferably $R_9$ is in position 1; preferably $R_8$ is in position 3.

When $R_c$ has a CH$_2$ replaced by CR$_x$R$_y$, it is preferably the CH$_2$ bearing Y.

Examples of heterocyclic residue as $R_1$, $R_4$, $R_7$, $R_8$, $R_{11}$, $R_{14}$ or Y or formed, respectively, by NR$_{16}$R$_{17}$ or NR$_{19}$R$_{20}$, include e.g. a residue of formula $\gamma$

\[
\begin{aligned}
\text{X}_6 \\
\text{D} \\
\text{C}_9 \\
\end{aligned}
\]

\[
\text{C}_2 \\
\text{C}_1 \\
\end{aligned}
\]

\[
\text{X}_5 \\
\text{X}_6 \\
\end{aligned}
\]

\[
(\gamma)
\]
wherein
the ring D is a 5, 6 or 7 membered saturated, unsaturated or aromatic ring;
X₆ is -N-, -C= or -CH₂;
X₇ is -N═, -NH, -NRᵣ, -CRᵣ═ or -CHRᵣ═ wherein Rᵣ is a substituent as indicated above for a
ring nitrogen atom, and Rᵣ is a substituent as indicated above for a ring carbon atom;
the bond between C₁ and C₂ is either saturated or unsaturated;
each of C₁ and C₂, independently, is a carbon atom which is optionally substituted by one or
two substituents selected among those indicated above for a ring carbon atom; and
the line between C₃ and X₆ and between C₁ and X₆, respectively, represents the number of
carbon atoms as required to obtain a 5, 6 or 7 membered ring D.
A preferred residue of formula (γ) is one wherein the ring D forms a 1,4-piperazinyl ring
optionally C- and/or N-substituted as indicated.

Representative examples of a residue of formula (γ) are e.g. 3- or 4- pyridyl; piperidin-1-yl; 1-
N-(C₁₄alkyl)- or -(ω-hydroxy-C₁₄alkyl)-3-piperidyl; morpholin-4-yl; imidazolyl; pyrrolidinyl; 1-
piperazinyl; 2-C₁₄alkyl- or C₃₆cycloalkyl-1-piperazinyl ;3-C₁₄alkyl- or C₃₆cycloalkyl-1-
piperazinyl; 2,2- or 3,5- or 2,5- or 2,6-di(C₁₄alkyl)-1-piperazinyl; 3,4,5-tri(C₁₄alkyl)-1-
piperazinyl; 4-N-(C₁₄alkyl)- or -(ω-hydroxy-C₁₄alkyl)- or -(ω-dimethylamino-C₁₄alkyl)-1-
piperazinyl; 4-N-pyridin-4-yl-1-piperazinyl; 4-N-phenyl- or C₃₆cycloalkyl-1-piperazinyl; 4-N-
(C₁₄alkyl)- or -(ω-hydroxy-C₁₄alkyl)-3-C₃₆cycloalkyl- or -3,3-di(C₁₄alkyl)-1-piperazinyl; 4-N-(1-C₁₄-
alkyl-C₃₆cycloalkyl)-1-piperazinyl; 4-N-formyl-1-piperazinyl; 4-N-pyrimidin-2-yl-1-piperazinyl;
4-N-C₁₄alkyl-1-homopiperazinyl; or 4,7-diaza-spiro [2.5] oct-7-yl.

The compounds of formula I may exist in free form or in salt form, e.g. addition salts with
e.g. organic or inorganic acids, for example, hydrochloric acid, acetic acid, when R₁, R₄, R₇,
R₈, R₁₁ or R₁₄ and/or R₉, R₉, R₂, R₉, R₉, R₁₀, R₁₂, R₁₃ or R₁₅ comprises an optionally
substituted amino group or a heterocyclic residue which can form acid addition salts.

It will be appreciated that the compounds of formula I may exist in the form of optical
isomers, racemates or diastereoisomers. For example, a ring carbon atom bearing a
substituent in the heterocyclic residue as R₁, R₄, R₇, R₈, R₁₁, R₁₄ or Y or formed, respectively,
by NR₁₅R₁₇ or NR₁₉R₂₀, is asymmetric and may have the D- or L- configuration. It is to be
understood that the present invention embraces all enantiomers and their mixtures. Similar
considerations apply in relation to starting materials exhibiting asymmetric carbon atoms as
mentioned.
In the compounds of formula I, the following significances are preferred individually or in any sub-combination:

1. $\text{R}_3$ is H or CH$_3$;
2. $\text{R}_6$ is H;
3. Ring A is unsubstituted; or is substituted by methyl in position 7;
4. Preferred heterocyclic residue as formed by $\text{NR}_{19}\text{R}_{20}$ is e.g. piperazin-1-yl optionally N-substituted, e.g. by C$_{1-4}$alkyl, ω-hydroxy-C$_{1-4}$alkyl, ω-dimethylamino-C$_{1-4}$alkyl, C$_5$-cycloalkyl, C$_{1-4}$alkyl-C$_5$-cycloalkyl, an aromatic heterocyclic residue comprising 1 or 2 nitrogen atoms, e.g. pyridyl or pyrimidin-2-yl or 4,7-diaza-spiro [2.5] oct-7-yl; or a residue of formula β as defined above and/or optionally C-substituted, e.g. by CH$_3$ e.g. in positions 2, and/or 3 and/or 5 and/or 6 and/or 2,2 or 3,3 or by $\text{C}_5$H$_5$, e.g. in position 2 or 3; piperidin-1-yl optionally C-substituted, e.g. in position 4, by NH$_2$, -CH$_2$-NH$_2$ or piperidin-1-yl, or in position 3, e.g. by OH or NH$_2$; or pyrrolidinyl optionally C-substituted in position 3 by OH or NH$_2$;
5. $\text{R}_{19}$ is H or CH$_3$;
6. $\text{R}_c$ is C$_{1-4}$alkylene or C$_{1-4}$alkylene wherein the terminal CH$_2$ is replaced by CR$_x$R$_y$ wherein $\text{R}_x$ and $\text{R}_y$ form together -CH$_2$-CH$_2$-
7. X is O;
8. The radical of formula (α) is –O-CH$_2$-CH$_2$-Y;
9. Each of $\text{R}_{19}$ and $\text{R}_{20}$ is H, C$_{1-4}$alkyl, e.g. methyl, C$_{1-4}$alkyl substituted on the terminal carbon atom by OH, e.g. -CH$_2$-CH$_2$-OH, or cyclopropyl;
10. Preferred heterocyclic residue as formed by $\text{NR}_{19}\text{R}_{20}$ is e.g. piperazin-1-yl optionally N-substituted by C$_{1-4}$alkyl or a residue of formula β; piperidin-1-yl; 1-(C$_{1-4}$alkyl)-piperidin-3-yl; 3- or 4-pyridyl; imidazolyl; pyrrolidinyl; or morpholin-4-yl;
11. Each of $\text{R}_1$, $\text{R}_4$, $\text{R}_7$, $\text{R}_8$, $\text{R}_{11}$ or $\text{R}_{14}$, independently, is 1-N-methyl-piperidin-4-yl; 4-methyl-piperazin-1-yl; 4-methyl-1-homopiperazinyl; 4-(2-hydroxyethyl)-piperazin-1-yl; or -X-C$_1$-$\text{C}_2$-$\text{C}_3$-alkylene-NR$_{19}$R$_{20}$ wherein X’ is a direct bond, O or NH;
12. In the residue of formula (a) either each of $\text{R}_2$ and $\text{R}_3$ is H or one of $\text{R}_2$ and $\text{R}_3$ is H and the other is F, Cl, CH$_3$, OH, OCH$_3$ or CF$_3$;
13. In the residue of formula (a) $\text{R}_2$ is OH;
14. In the residue of formula (b) either each of $\text{R}_5$ and $\text{R}_6$ is H or one of $\text{R}_5$ and $\text{R}_6$ is H and the other is F, Cl, CH$_3$, OCH$_3$ or CF$_3$;
15. In the residue of formula (b) R₄ is a radical of formula (α) or NR₁⁰R₁₇;
16. In the residue of formula (d) either each of R₉ and R₁₆ is H or one of R₉ and R₁₀ is H and
the other is F, Cl, CH₃, OCH₃ or CF₃; preferably R₁₀ is H and R₉ is in position 5, 6, 7 or 8,
preferably in position 6;
17. In the residue of formula (e) each of R₁₂ and R₁₃ is H;
18. In the residue of formula (e) one of R₁₂ and R₁₃ is H and the other is F, Cl, CH₃, OCH₃ or
CF₃;

when E is –N= and G is –CH=, preferably R₁₃ is H and R₁₂ is in position 6 or 7;
when E is –CH= and G is –N=, preferably R₁₃ is H and R₁₂ is in position 7;
19. In the residue of formula (f) R₁₅ is H, CH₃ or Cl, e.g. in position 5 or 6;
20. In the residue of formula (f) R'₁₅ is H or CH₃, e.g. in position 5, preferably H;
21. R is a radical of formula (d), (e) or (f).

Compounds of formula I and their preparation are known, e.g. they are disclosed in
WO02/38561 and WO03/82859, the contents thereof being incorporated herein by
reference.

According to the invention, there is provided a solid pharmaceutical composition suitable for
oral administration comprising from 20 to 70%, preferably 20 to 55% by weight of a water
sensitive drug, preferably an indolylmaleimide derivative and most preferred a compound of
formula I in free form or in pharmaceutically acceptable salt, preferably from 15 to 80%,
preferably 20 to 70%, more preferably 22 to 55%, even more preferably from 25 to 52%, e.
g. 35 to 52% by weight, based on the total weight of the composition, the total weight of the
composition being, in case of a tablet, the total tablet core weight.

One or more pharmaceutically acceptable carriers or diluents may be present in the solid
pharmaceutical compositions, e. g. at least one filler; at least one disintegrant; at least one
glidant; at least one lubricant; and optionally, at least one binder and/or a surfactant.

Fillers according to the invention include e.g. lactose, especially lactose monohydrate,
preferably lactose monohydrate (200mesh) or lactose spray dried, microcrystalline cellulose,
e.g. PH 102, PH 101, microcrystalline silicified cellulose, starch, calcium phosphate, or a
saccharide, e.g. mannitol, maltodextrin or maltose, or a mixture thereof. Preferably, lactose
spray dried, microcrystalline cellulose or microcrystalline silicified cellulose, more preferably
lactose spray dried and microcrystalline cellulose or lactose spray dried and microcrystalline silicified cellulose is used.

The composition of the invention preferably contains from 15 to 65%, preferably 35 to 65% by weight of a filler, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Thus, a particularly suitable solid pharmaceutical composition contains as filler (a) from 18 to 31% by weight of lactose spray dried and from 18 to 31% by weight of microcrystalline cellulose or (b) from 18 to 31% by weight of lactose spray dried and from 23 to 31% by weight of microcrystalline silicified cellulose, calcium phosphate, or a saccharide, e.g. as mentioned previously, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

Disintegrants according to the invention include e.g. natural starches, such as maize starch, potato starch, and the like, directly compressible starches, e.g. Sta-RX 1500, modified starches, e.g. carboxymethyl starches and sodium starch glycolate, starch derivatives such as amylase, crosslinked polyvinylpyrrolidones, e.g. crospovidones, e.g. Polypasdone® XL or Kollidon® CL, alginic acid or sodium alginate, methacrylic acid divinylbenzene copolymer salts, e.g. AMBERLITE i9 IRP-88, or cross-linked sodium carboxymethylcellulose, available as e.g. AC-DI-SOL; COMMAT; PRIMELLOSEF, PHARMACEL, EXPLOCEL, or NYMCEL ZSX. Preferably, directly compressible starches, such as Sta-RX 1500 is used.

The composition of the invention preferably contains from 5 to 15% by weight of a disintegrant, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Thus, a particularly suitable solid pharmaceutical composition contains as disintegrant from 5 to 15% by weight of a directly compressible starch, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

Binders according to the invention include starches, e.g. potato, wheat or corn starch; hydroxypropyl cellulose; hydroxyethyl cellulose; hydroxypropylmethyl cellulose, e.g. hydroxypropylmethyl cellulose-Type 2910 USP, hypromellose, and polyvinylpyrrolidone, e.g. Povidone K30 from BASF. Preferably, hydroxypropylmethyl cellulose or polyvinylpyrrolidone 30 is used.
The composition of the invention may contain from 0 to 5% by weight, preferably from 1 to 5% by weight, of a binder based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Thus, a particularly suitable solid pharmaceutical composition contains as binder (a) from 0 to 3% by weight of hydroxypropyl methyl cellulose or (b) from 0 to 5% by weight of polyvinylpyrrolidone 30, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

The composition of the invention may contain from 0 to 3% of a surfactant based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Surfactants according to the invention include e.g. an anionic, cationic or non-ionic surfactant or a mixture thereof, e.g. sodium lauryl sulfate, cetrimide, a polysorbate or a sorbitan fatty acid ester, e.g. a sorbitan fatty acid ester from a fatty acid such as oleic, stearic or palmitic acid.

Glidants according to the invention include e.g. silica, colloidal silica, e.g. colloidal silicon dioxide, e.g. AEROSIL 200, magnesium trisilicate, powdered cellulose, starch and talc. Preferably, colloidal silicon dioxide is used.

The composition of the invention preferably contains from 0.5 to 1% by weight of a glidant, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Thus, a particularly suitable solid pharmaceutical composition contains as glidant from 0.5 to 1% by weight of colloidal silicone dioxide, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

Lubricants according to the invention include e.g. Mg-, Al- or Ca-stearate, PEG 4000-8000, talc, sodium benzoate, glyceryl mono fatty acid, e.g. having a molecular weight of from 200 to 800 Daltons, e.g. glyceryl monostearate (e.g. Danisco, UK), glyceryl dibehenate (e.g. COMPPLITOLAT™ 0888, Gattefossé France), glyceryl palmito-stearic ester (e.g. PRECIROL™, Gattefossé France), polyoxyethylene glycol (PEG, BASF), hydrogenated cotton seed oil (Lubritrab, Edward Mendell Co Inc) and castor seed oil (Cutina HR, Henkel). Preferably, magnesium stearate is used.
The composition of the invention preferably contains from 0.5 to 2% by weight of a lubricant, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight. Thus, a particularly suitable solid pharmaceutical composition contains as lubricant from 0.5 to 2% by weight of magnesium stearate, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

The composition of the invention may be in the form of a powder, granule or pellets or a unit dosage form, for example a tablet or capsule. Preferably, the solid pharmaceutical composition of the invention is in the form of a tablet. The composition of the present invention is well-adapted for direct compression into tablets. The tablets may optionally be coated, for instance with a coating comprising, a polysaccharide, e.g. cellulose, hydroxypropyl-methylcellulose, e.g. HMPC 603, polyoxyethylene glycol, e.g. PEG 6000 or PEG 8000, one or more dyers, carnauba wax, or an aluminium lake.

The composition of the invention may show good stability characteristics as indicated by standard stability trials, for example having a shelf life stability of up to one, two or three years, and even longer. Stability characteristics may be determined, e.g. by measuring decomposition products by HPLC analysis after storage for particular time periods, at various temperatures, e.g. 20°, 40° or 60°C.

The composition of the present invention may be produced by standard processes, for instance by conventional mixing, compacting, granulating, compression, or coating with or without sugar. Procedures which may be used are known in the art, e.g. those described in L. Lachman et al. The Theory and Practice of Industrial Pharmacy, 3rd Ed, 1986, H. Sucker et al, Pharmazeutische Technologie, Thieme, 1991, Hagers Handbuch der pharmazeutischen Praxis, 4th Ed. (Springer Verlag, 1971) and Remington's Pharmaceutical Sciences, 13th Ed. (Mack Publ., Co., 1970) or later editions.

In one aspect, the present invention relates to a process for producing a composition of the invention, comprising: (a) mixing a water sensitive drug, preferably an indolylmaleimide
derivative with a filler, a disintegrant, a glidant and, optionally, a binder; (b) milling and/or granulating or compacting the mixture obtained in (a); and (c) mixing the milled and/or granulated mixture obtained in (b) with a lubricant.

By using this process, a preparation having a good level of content and blend uniformity (i.e. a substantially uniform distribution of the water sensitive drug, preferably an indolylmaleimide derivative throughout the composition), dissolution time and stability is obtained.

The process may be carried out by dry mixing the components. In this embodiment the milling step (b) may suitably comprise passing the mixture obtained in (a) through a screen, which preferably has a mesh size of 900 to 1000 µm.

The lubricant, e.g. magnesium stearate, is preferably pre-screened, e.g. with a 800 to 900 µm screen, before mixing.

Alternatively, a wet granulation process may be employed. In this embodiment, the drug is preferably first dry-mixed with the further components of the composition. Water or a granulation liquid is then added and the mixture granulated, e.g. using an automated granulator. The granules are then dried and milled.

The composition of the tablet, e.g. the tablets or capsules, may be coloured or marked so as to impart an individual appearance and to make them instantly recognizable. The use of dyes can serve to enhance the appearance as well as to identify the forms. Dyes suitable for use in pharmacy typically include e.g. carotinoids, iron oxides, chlorophyll, titanium dioxide or aluminium lakes.

The composition of the invention may be used for the treatment or prevention of the diseases for which the active agent it contains, is useful. Thus, the composition of the invention comprising an indolylmaleimide derivative of formula I may be used in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or
adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases, e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto’s thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitis, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjögren’s syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn’s disease or ulcerative colitis.

For the above uses the required dosage will of course vary depending on the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.1 to about 100 mg/kg body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 2000 mg, conveniently administered, for example, in divided doses up to four times a day.

The composition of the invention may be administered in conjunction with a co-agent depending on the diseases or disorders to be treated and the active agent present in the composition. The composition of the invention comprising an indolylmaleimide derivative of formula I may be administered in conjunction, either simultaneously or in sequence, with other drugs in immunomodulating regimens or other anti-inflammatory agents e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders. For example, they may be used in combination with cyclosporines, or ascomycines or their immunosuppressive analogs or derivatives, e.g. cyclosporin A, cyclosporin G, FK-506, ABT-281, ASM 981; an mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxy-ethyl)-rapamycin, CCI779, ABT578, biolimus-7, biolimus-9, TAFA-93, AP23573, AP23464 or AP23841 etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; a S1P receptor modulator, e.g. FTY 720 or an analogue thereof; leflunomide or analogs thereof; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxy-spergualine or analogs thereof; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to
leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD 11a/CD18, CD7, CD25, CD 27, B7, CD40, CD45, CD58, CD 137, ICOS, CD150 (SLAM), OX40, 4-1BB or their ligands, e.g. CD154; or other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein-sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including LFA-1 antagonists, Selectin antagonists and VLA-4 antagonists. The composition of the invention comprising an indolylmaleimide derivative of formula I may also be administered in conjunction with, e.g. simultaneously or in sequence, an antiproliferative drug, e.g. a chemotherapeutic drug, e.g. in cancer treatment, or with an anti-diabetic drug in diabetes therapy. Dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic agent may vary depending on the type of the co-agent used, on the specific drug employed, on the condition being treated and so forth.

In accordance with the foregoing the present invention further provides:

1.1 A solid pharmaceutical composition suitable for oral administration, as defined above, for use in preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC, e.g. such as indicated above, in a subject in need of such treatment.

2.1 A method for preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC, e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a solid pharmaceutical composition suitable for oral administration as defined above.

2.2 A method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a solid pharmaceutical composition suitable for oral administration as defined above.

2.3 A method for preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC, e.g. such as indicated above, in a subject in need of such treatment, which method comprises co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a solid pharmaceutical composition suitable for oral administration as defined above, and a second drug substance, said second drug
substance being an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug, e.g. as indicated above.

3. A therapeutic combination, e.g. a kit, comprising a) a solid pharmaceutical composition suitable for oral administration as defined above, and b) at least one second agent selected from an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative and anti-diabetic drug. Component a) and component b) may be used concomitantly or in sequence. The kit may comprise instructions for its administration.

4. Use of a solid pharmaceutical composition suitable for oral administration as defined above for the preparation of a medicament for the prevention or treatment of disorders or diseases mediated by T lymphocytes and/or PKC, e.g. such as indicated above.

The invention will now be described with reference to the following specific embodiments.

The following Examples are illustrative of the instant invention, without limiting.

Compound A: 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione acetate salt

Sta-RX 1500: directly compressible starch from Colorcon.

Example 1
250 g of Compound A is mixed with 200 g lactose spray dried, 200 g microcrystalline cellulose, 12.5 g hydroxypropyl methyl cellulose 3 cps, 40 g Star-RX 1500 and 2.5 g colloidal silicon dioxide (Aerosil 200) and subsequently screened. The mixture is then milled in a Frewitt MGI device (Key International Inc. USA) using a 1000 μm mesh screen. Magnesium stearate is screened using a 800 μm mesh screen and 5 g of the screened magnesium stearate is blended with the Compound A mixture to produce a product composition. The product composition is then compacted on a tablet press using a 18 mm long die to form 250 mg strength tablets, each containing: 250 mg Compound A, 200 mg lactose spray dried, 200 mg cellulose microcrystalline, 12.5 mg hydroxypropyl methyl cellulose 3 cps, 40 mg Star-RX 1500 and 2.5 mg colloidal silicon dioxide, 5 mg magnesium stearate. Finally, a conventional water-based film coat is applied.
Example 2:
In a further example, the process of example 1 is repeated except that the microcrystalline cellulose is replaced by microcrystalline silicified cellulose.

Example 3:
In a further example, the process of example 1 is repeated except that the hydroxypropylmethyl cellulose is replaced by polyvinylpyrrolidone 30.

Example 4:
The procedure of Examples 1 to 3 is repeated, except that Compound A is replaced by 3-(1H-indol-3-yl)-4-[2-(piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione.

Example 5:
The procedure of Examples 1 to 3 is repeated, except that Compound A is replaced by 3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.
1. A solid pharmaceutical composition suitable for oral administration comprising an indolylmaleimide derivative of formula I

![Chemical Structure](image)

wherein

- $R_a$ is H; C$_{14}$-alkyl; or C$_{14}$-alkyl substituted by OH, NH$_2$, NHC$_{14}$-alkyl or N(di-C$_{14}$-alkyl)$_2$;
- $R_b$ is H; or C$_{14}$-alkyl;
- $R$ is a radical of formula (a), (b), (c), (d), (e) or (f)

![Radical Structures](images)

wherein

- each of $R_1, R_4, R_7, R_9, R_{11}$ and $R_{14}$ is OH; SH; a heterocyclic residue; NR$_{16}$R$_{17}$ wherein each of $R_{16}$ and $R_{17}$, independently, is H or C$_{14}$-alkyl or R$_{16}$ and R$_{17}$ form together with the nitrogen atom to which they are bound a heterocyclic residue; or a radical of formula $\alpha$ $-X-R_X-Y$ $\beta$

wherein $X$ is a direct bond, O, S or NR$_{16}$ wherein R$_{18}$ is H or C$_{14}$-alkyl,
- $R_c$ is C$_{14}$-alkylene or C$_{14}$-alkylene wherein one CH$_2$ is replaced by CR$_{15}R_{16}$ wherein one of $R_x$ and $R_y$ is H and the other is CH$_3$, each of $R_x$ and $R_y$ is CH$_3$ or $R_x$ and $R_y$ form together $-CH_2-CH_2-$, and
Y is bound to the terminal carbon atom and is selected from OH, a heterocyclic residue
and -NR_{19}R_{20} wherein each of R_{19} and R_{20} independently is H, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, aryl-C_{1-4}alkyl or C_{1-4}alkyl optionally substituted on the terminal
carbon atom by OH, or R_{19} and R_{20} form together with the nitrogen atom to which they
are bound a heterocyclic residue;
each of R_{2}, R_{3}, R_{5}, R_{6}, R_{8}, R_{10}, R_{12}, R_{13}, R_{15} and R'_{15}, independently, is H, halogen, C_{1-4}alkyl,
CF_{3}, OH, SH, NH_{2}, C_{1-4}alkoxy, C_{1-4}alkylthio, NH_{2}C_{1-4}alkyl, N(di-C_{1-4}alkyl)_{2} or CN;
either E is --N= and G is --CH= or E is --CH= and G is --N=; and
ring A is optionally substituted,
in free form or in pharmaceutically acceptable salt.

2. A composition according to claim 1 wherein the composition comprises 20 to 70% by
weight of the indolymaleimide derivative, based on the total weight of the composition, the
total weight of the composition being, in case of a tablet, the total tablet core weight.

3. A composition according to claim 1 or claim 2 comprising in addition at least one filler.

4. A composition according to claim 3 wherein the composition comprises from 15 to 65%
by weight of the filler, based on the total weight of the composition, the total weight of the
composition being, in case of a tablet, the total tablet core weight.

5. A composition according to any preceding claim comprising at least one disintegrant.

6. A composition according to claim 5 wherein the composition comprises from 5 to 15%
by weight of the disintegrant, based on the total weight of the composition, the total weight of the
composition being, in case of a tablet, the total tablet core weight.

7. A composition according to any preceding claim comprising at least one glidant.

8. A composition according to claim 7 wherein the composition comprises from 0.5 to 1%
by weight of the glidant, based on the total weight of the composition, the total weight of the
composition being, in case of a tablet, the total tablet core weight.

9. A composition according to any preceding claim comprising at least one lubricant.
10. A composition according to claim 9 wherein the composition comprises from 0.5 to 2% by weight of the lubricant, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

11. A composition according to any preceding claim comprising at least one binder.

12. A composition according to claim 11 wherein the composition comprises from 0 to 5% by weight of the binder, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

13. A composition according to any preceding claim comprising at least one surfactant.

14. A composition according to claim 13 wherein the composition comprises from 0 to 3% by weight of the surfactant, based on the total weight of the composition, the total weight of the composition being, in case of a tablet, the total tablet core weight.

15. A composition according to any one of claims 3 to 14 wherein the filler is selected from lactose, microcrystalline cellulose, microcrystalline silicified cellulose, starch, calcium phosphate and saccharide.

16. A composition according to one of claims 5 to 15 wherein the disintegrant is selected from natural starches, directly compressible starches, modified starches, starch derivatives, crosslinked polyvinylpyrrolidones, alginic acid or sodium alginate, methacrylic acid divinylbenzene copolymer salts and cross-linked sodium carboxymethylcellulose.

17. A composition according to any one of claims 7 to 16 wherein the glidant is selected from silica, colloidal silica, magnesium trisilicate, powdered cellulose, starch and talc.

18. A composition according to any of claims 9 to 17 comprising magnesium stearate as lubricant.
19. A composition according to any one of claims 11 to 18 wherein the binder is selected from starches, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hypromellose and polyvinylpyrrolidone.

20. A composition according to any of claims 1 to 19 wherein the composition is in the form of a capsule or a tablet, the tablet being optionally coated.

21. A composition according to any of claims 1 to 20, wherein the indolylmaleimide derivative comprises 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof.

22. A composition according to any of claims 1 to 20, wherein the indolylmaleimide derivative comprises 3-(1H-indol-3-yl)-4-[2-(piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof.

23. A composition according to any of claims 1 to 20, wherein the indolylmaleimide derivative comprises 3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof.

24. A composition according to any of claims 1 to 23 for use in preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC in a subject in need of such treatment.

25. A process for producing a solid pharmaceutical composition suitable for oral administration according to any of claims 7 to 23 comprising: (a) mixing an indolylmaleimide derivative of formula I as defined in claim 1 with a filler, a disintegrant, a glidant and, optionally, a binder; (b) mixing, dry compacting, milling, granulating, drying or compacting the mixture obtained in (a); (c) mixing the mixture obtained in (b) with a lubricant; (d) optionally tableting and (e) optionally coating.

26. A process according to claim 25 wherein in step (b) the mixture is wet granulated, roller compacted or compressed.
27. A method for preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a solid pharmaceutical composition suitable for oral administration according to any one of claims 1 to 23.

28. A use of a solid pharmaceutical composition suitable for oral administration according to any one of claims 1 to 23 for the preparation of a medicament for the prevention or treatment of disorders or diseases mediated by T lymphocytes and/or PKC.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/404  A61K9/20

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 02/38561 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; ALBER) 16 May 2002 (2002-05-16) cited in the application claims 1-11 page 1 - page 36</td>
<td>1,21-28</td>
</tr>
</tbody>
</table>

[ ] Further documents are listed in the continuation of Box C.  [ ] See patent family annex.

* Special categories of cited documents:
- **A** document defining the general state of the art which is not considered to be of particular relevance
- **E** earlier document but published on or after the international filing date
- **L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- **O** document referring to an oral disclosure, use, exhibition or other means
- **P** document published prior to the international filing date but later than the priority date claimed

- **T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- **X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- **Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a skilled person in the art.
- **&** document member of the same patent family

Date of the actual completion of the international search 19 June 2006

Date of mailing of the international search report 04/07/2006

Name and mailing address of the ISA/ European Patent Office, P.O. Box 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel: (+31-70) 940-1040, Tx: 31 651 epo nl, Fac: (+31-70) 340-3016

Authorized officer Schifferer, H
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 03/082859 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; EVENOU, JEAN-PIERRE; VON MATT, PETE) 9 October 2003 (2003-10-09) claims 1-10 page 1 - page 15</td>
<td>1-28</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BR 0115193 A</td>
<td>03-02-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2428133 A1</td>
<td>16-05-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1478087 A</td>
<td>25-02-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1337527 A1</td>
<td>27-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004513168 T</td>
<td>30-04-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA03004037 A</td>
<td>19-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20032034 A</td>
<td>04-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 525656 A</td>
<td>24-12-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 361409 A1</td>
<td>04-10-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 5462003 A3</td>
<td>04-11-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0113916 A1</td>
<td>01-03-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0308979 A</td>
<td>04-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2477774 A1</td>
<td>09-10-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1639153 A</td>
<td>13-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1490355 A1</td>
<td>29-12-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005527563 T</td>
<td>15-09-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA04009632 A</td>
<td>11-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005119274 A1</td>
<td>02-06-2005</td>
</tr>
</tbody>
</table>

*See PCT/ISA/212 (patent family annex) (April 3009)*